Kenji Imamachi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kenji Imamachi has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hironobu Hata
Department of Dentistry and Oral Surgery NHO Hokkaido Cancer Center Sapporo Hokkaido Japan
4 shared publications Kazuhito Yoshikawa
Department of Dentistry and Oral Surgery, NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
4 shared publicationsKatsuya Fujimoto
Department of Hematology, NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
3 shared publications- Masashi Matsuzaka
Department of Medical Informatics Hirosaki University Graduate School of Medicine Hirosaki Japan
3 shared publications Satoshi Oizumi
Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
3 shared publications- Toshihisa Osanai
Department of Rehabilitation, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan
3 shared publications
Latest Publications
- 14 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 94
Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study
Purpose Discontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ. Methods We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed. Results The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups. Conclusion A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.
- 14 January 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (2) , 94
Efficacy and risks of drug holiday in the management of medication-related osteonecrosis of the jaw in cancer patients: a single-center retrospective study
Purpose Discontinuing bone-modifying agents (BMAs) during management of medication-related osteonecrosis of the jaw (MRONJ) remains controversial. This retrospective study evaluates the impact and potential risks of BMA drug holidays in cancer patients with MRONJ. Methods We retrospectively classified 156 cancer patients with MRONJ into four groups: BMA withdrawal with conservative therapy (WC, n = 40), withdrawal with surgical therapy (WS, n = 63), non-withdrawal with conservative therapy (nWC, n = 30), and non-withdrawal with surgical therapy (nWS, n = 23). In the WS group, surgery was performed after radiographic confirmation of bone sequestration following BMA discontinuation. Healing rates and skeletal-related events (SREs) incidence were analyzed. Results The healing rates from MRONJ onset were 94.7% in the WS group, 53.6% in the nWS group, 25.5% in the WC group, and 0% in the nWC group. Among surgical patients, the healing rate from the time of surgery was significantly higher in the WS group (92.3%) than in the nWS group (47.8%) (hazard ratio = 3.23, p < 0.05). The incidence of SREs was 52.3% in the WC group, 15.8% in the WS group, 16.7% in the nWS group, and 4.2% in the nWC group. The WC group showed a significantly higher incidence of SREs compared with the WS and nWS groups. Conclusion A therapeutic strategy involving planned BMA discontinuation followed by delayed surgical intervention after radiographic confirmation of sequestrum formation, may be associated with improved healing outcomes. This approach does not appear to increase the incidence of SREs, particularly when BMA therapy is appropriately resumed after successful surgical healing.
- 1 November 2024
- Published by Elsevier in Journal of Oral Biosciences
- Vol. 67 (1) , 100585
Apoptotic cell death during regressive changes in salivary glands: A morphological perspective
- 1 November 2024
- Published by Elsevier in Journal of Oral Biosciences
- Vol. 67 (1) , 100585
Apoptotic cell death during regressive changes in salivary glands: A morphological perspective
- 1 November 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9693-9695
Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points
- 1 November 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9693-9695
Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points
- Open Access
- 3 March 2022
- Published by Springer Nature in BMC Oral Health
- Vol. 22 (1) , 1-6
Oral adverse events due to zinc deficiency after pancreaticoduodenectomy requiring continuous intravenous zinc supplementation: a case report and literature review
Background: Zinc is mainly absorbed in the duodenum and proximal jejunum, which are removed during pancreaticoduodenectomy (PD). Little is known about the adverse oral events and skin disorders caused by zinc deficiency after PD. Herein, we reviewed studies on the development of zinc deficiency after PD and reported about a patient with zinc deficiency after PD who required home intravenous zinc replacement. Case presentation: A 73-year-old woman with glossitis, taste disorder, and acrodermatitis enteropathica-like eruption on her fingers presented to the Division of Dentistry and Oral Surgery 69 days after PD. Her serum zinc level markedly decreased to 30 μg/dL. Oral zinc administration was inadequate to treat hypozincemia after PD; therefore, multi-trace elements were injected intravenously during readmission. Her serum zinc levels recovered, and her lesions gradually improved. Furthermore, a central venous port was implanted to maintain normal serum zinc levels, and she continued self-injecting zinc at home. Conclusions: Zinc deficiency after PD rarely occurs. The clinical oncologist community, including dentists responsible for the oral care of cancer patients, should be aware of the oral adverse events, such as dysgeusia, glossitis, and oral pain, associated with zinc deficiency after cancer surgery and that induced by chemotherapy or head and neck radiation therapy.
- 3 March 2022
- Published by Springer Nature in BMC Oral Health
- Vol. 22 (1) , 1-6
Open AccessOral adverse events due to zinc deficiency after pancreaticoduodenectomy requiring continuous intravenous zinc supplementation: a case report and literature review
Background: Zinc is mainly absorbed in the duodenum and proximal jejunum, which are removed during pancreaticoduodenectomy (PD). Little is known about the adverse oral events and skin disorders caused by zinc deficiency after PD. Herein, we reviewed studies on the development of zinc deficiency after PD and reported about a patient with zinc deficiency after PD who required home intravenous zinc replacement. Case presentation: A 73-year-old woman with glossitis, taste disorder, and acrodermatitis enteropathica-like eruption on her fingers presented to the Division of Dentistry and Oral Surgery 69 days after PD. Her serum zinc level markedly decreased to 30 μg/dL. Oral zinc administration was inadequate to treat hypozincemia after PD; therefore, multi-trace elements were injected intravenously during readmission. Her serum zinc levels recovered, and her lesions gradually improved. Furthermore, a central venous port was implanted to maintain normal serum zinc levels, and she continued self-injecting zinc at home. Conclusions: Zinc deficiency after PD rarely occurs. The clinical oncologist community, including dentists responsible for the oral care of cancer patients, should be aware of the oral adverse events, such as dysgeusia, glossitis, and oral pain, associated with zinc deficiency after cancer surgery and that induced by chemotherapy or head and neck radiation therapy.
- 3 February 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (5) , 4505-4514
Prognosis by cancer type and incidence of zoledronic acid–related osteonecrosis of the jaw: a single-center retrospective study
Purpose Survival time after bisphosphonate use has been increasingly recognized to be associated with the incidence of medication-related osteonecrosis of the jaw (MRONJ); however, this has not been elucidated sufficiently in the literature. This study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid (ZA) for each type of cancer and obtain useful information for the oral/dental supportive care of cancer patients. Methods We evaluated 988 patients who were administered ZA at our hospital; among them, 862 patients with metastatic bone tumors or myeloma were included. Results The median survival time (MST) after ZA initiation was 35, 34, 8, 41, 12, and 6 months for patients with breast, prostrate, lung, myeloma, renal, and other cancers, respectively. Patients with cancers that had a short survival time (lung and other cancers [MST = 8 and 6 months, respectively] and cancers with MST < 10 months) did not develop MRONJ; this could be attributed to the shorter duration of ZA administration. The cumulative incidence of MRONJ in breast cancer, prostate cancer, and multiple myeloma was related to the frequency of anti-resorptive drug use and the increased risk over time. In renal cancer, the cumulative incidence of MRONJ increased early, although the MST was 12 months. Conclusion For the dentists in charge of dental management, it is essential to be aware of prognosis-related factors, predict MRONJ risk for each cancer treatment, and use risk prediction in dental management planning, particularly for cancers with non-poor prognosis.
- 3 February 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (5) , 4505-4514
Prognosis by cancer type and incidence of zoledronic acid–related osteonecrosis of the jaw: a single-center retrospective study
Purpose Survival time after bisphosphonate use has been increasingly recognized to be associated with the incidence of medication-related osteonecrosis of the jaw (MRONJ); however, this has not been elucidated sufficiently in the literature. This study aimed to clarify the incidence of MRONJ and the corresponding survival rate of patients treated with zoledronic acid (ZA) for each type of cancer and obtain useful information for the oral/dental supportive care of cancer patients. Methods We evaluated 988 patients who were administered ZA at our hospital; among them, 862 patients with metastatic bone tumors or myeloma were included. Results The median survival time (MST) after ZA initiation was 35, 34, 8, 41, 12, and 6 months for patients with breast, prostrate, lung, myeloma, renal, and other cancers, respectively. Patients with cancers that had a short survival time (lung and other cancers [MST = 8 and 6 months, respectively] and cancers with MST < 10 months) did not develop MRONJ; this could be attributed to the shorter duration of ZA administration. The cumulative incidence of MRONJ in breast cancer, prostate cancer, and multiple myeloma was related to the frequency of anti-resorptive drug use and the increased risk over time. In renal cancer, the cumulative incidence of MRONJ increased early, although the MST was 12 months. Conclusion For the dentists in charge of dental management, it is essential to be aware of prognosis-related factors, predict MRONJ risk for each cancer treatment, and use risk prediction in dental management planning, particularly for cancers with non-poor prognosis.